Buy Fragment 176-191, 5mg + bacteriostatic water 3 ml
€29.84
hGH Fragment 176–191, 5 mg, with 3 mL bacteriostatic water, is a disulphide-containing peptide for analytical and in vitro laboratory research. Pharma Research .eu provides documented European supply subject to sequence-specific purity and structural verification.
Buy hGH Fragment 176–191, 5 mg + Bacteriostatic Water, 3 mL, for Advanced Laboratory Research in Europe
hGH Fragment 176–191 is a synthetic 16-residue peptide corresponding to the C-terminal region of human growth hormone. It contains two cysteine residues capable of forming an intramolecular disulphide bridge and is analytically distinct from AOD-9604, which includes an additional N-terminal tyrosine. For this product, the exact sequence and salt form must be verified because commercial records report materially different molecular formulas and masses. Pharma Research .eu presents this 5 mg format with 3 mL bacteriostatic water for qualified European laboratories.pubchem.ncbi.nlm.nih+2
Uncompromising Purity and Analytical Characterisation
The principal sequence commonly associated with hGH Fragment 176–191 is:
H-Tyr-Leu-Arg-Ile-Val-Gln-Cys-Arg-Ser-Val-Glu-Gly-Ser-Cys-Gly-Phe-OH
The two cysteine residues form an intramolecular disulphide bridge in the oxidised material. However, supplier records also describe related forms with different terminal chemistry and molecular masses. The CoA must therefore identify the exact N-terminal residue, terminal groups, disulphide state and salt form before a definitive technical specification is published.
For laboratory procurement, the suitable target is ≥99.0% purity by RP-HPLC, subject to confirmation by the batch-specific certificate of analysis. A complete release package should also include LC-MS identity and, where relevant, confirmation of the disulphide state.uk-peptides+1
A complete CoA should include:
-
RP-HPLC purity percentage, analytical method and chromatogram.
-
LC-MS, ESI-MS or high-resolution MS identity confirmation.
-
Full sequence and terminal-group designation.
-
Oxidised versus reduced disulphide-state information.
-
Molecular formula and molecular-mass assignment.
-
Free-peptide, acetate or other salt-form information.
-
Visual appearance of the lyophilised material.
-
Residual-solvent results from synthesis and purification.
-
Water or residual-moisture content, where measured.
-
Heavy-metal or elemental-impurity results where included in the quality programme.
-
Lot number, manufacture date, retest date and storage requirements.
Public records report several forms. One source lists C₇₈H₁₂₇N₂₃O₂₄S₂ with a molecular mass near 1,859.1 Da, while another SDS lists C₇₈H₁₂₅N₂₃O₂₃S₂ and approximately 1,817.1 Da for an acetate-associated form. Other databases report approximately 1,799–1,817 Da depending on terminal and salt conventions. These discrepancies make CoA verification essential.pubchem.ncbi.nlm.nih+3
The peptide is generally supplied as a white to off-white lyophilised powder. Visual inspection can identify gross discolouration, vial damage or visible contamination, but cannot establish identity or disulphide integrity. Analytical release should combine appearance assessment with RP-HPLC, mass spectrometry and suitable reduction/oxidation controls.
High purity is important because reduced thiols, disulphide-scrambled species, truncated chains, aggregates and synthesis-related impurities can affect conformation, solubility and assay response. The product must also be distinguished from AOD-9604, which is a related but structurally different Tyr-modified fragment.watson-int+1
Principal Laboratory Applications and Research Methodologies
hGH Fragment 176–191 is suitable for controlled laboratory research involving disulphide-peptide chemistry, analytical characterisation and in vitro biochemical or cellular model development. All applications should be conducted by qualified personnel within an appropriately governed university, CRO, pharmaceutical R&D or analytical laboratory.
Disulphide identity and stability studies. Laboratories may assess intact mass, oxidation state, reduction behaviour and disulphide scrambling using LC-MS, RP-HPLC and validated reduction controls. These methods distinguish the intended oxidised peptide from altered forms.
RP-HPLC and LC-MS method development. The fragment can support retention-time assignment, impurity profiling, precursor-ion selection and product-ion optimisation. Methods should resolve intact peptide from reduced, scrambled, truncated and aggregated species.
In vitro biochemical and cellular models. A verified lot may be incorporated into controlled cell-free or cellular systems examining peptide-associated biochemical responses. Appropriate controls may include vehicle, matrix and reduced-peptide controls, depending on the research question.
Formulation and stability research. Laboratories may investigate the effects of pH, temperature, light, oxygen, reducing agents, container material and freeze–thaw exposure. Both peptide concentration and disulphide integrity should be monitored.
The 5 mg quantity corresponds to approximately 2.7–2.8 µmol depending on the exact molecular form. If the entire quantity were dissolved in 3 mL, the nominal concentration would be approximately 1.67 mg/mL, but the molar concentration cannot be stated reliably until the CoA confirms the formula and salt form.
These figures are formulation calculations for laboratory planning only. The actual concentration should be based on measured net content, purity, final volume and the validated preparation method. Bacteriostatic water should be evaluated for compatibility with the peptide’s redox state and intended assay.
Compound Stability, Optimal Storage, and Safe Handling Protocols
Lyophilised hGH Fragment 176–191 should remain sealed, dry and protected from light until required for a validated laboratory procedure. Research guidance commonly recommends storage at −20°C or below, with short-term 2–8°C storage used only where supported by the supplier’s documentation.peptidecompass+2
Recommended controls include:
-
Store unopened lyophilised material at −20°C unless the CoA specifies another condition.
-
Consider −80°C for extended archival storage where supported by the stability programme.
-
Keep the vial tightly closed, dry and protected from direct light.
-
Allow a sealed vial to reach room temperature before opening to minimise condensation.
-
Use low-binding, non-reactive containers where adsorption or thiol exchange could affect recovery.
-
Avoid reducing agents and unvalidated metal-containing buffers.
-
Prepare aliquots if repeated access is expected.
-
Store short-term aqueous solutions at 2–8°C only where validated.
-
Avoid repeated freeze–thaw cycles.
-
Monitor peptide concentration and disulphide state during stability studies.
-
Record solvent, pH, concentration, preparation date, operator and storage history.
The cysteine residues make redox conditions important. Reducing agents, dissolved oxygen, pH and trace metals can affect the disulphide bridge. Published commercial guidance gives different post-reconstitution windows, ranging from several days to a few weeks; these should not be treated as universal stability guarantees without product-specific analytical data.realpeptides+2
Reconstitution should be performed using a validated laboratory procedure. Add bacteriostatic water gradually, allow the powder to hydrate and mix gently. Avoid vigorous agitation and unvalidated reducing or chelating conditions. If turbidity, precipitation or unexpected colour change occurs, analyse the material before use.
Handling should follow the current SDS and institutional chemical-risk assessment. Appropriate precautions generally include a certified fume hood or suitable local containment, nitrile gloves, safety goggles and a laboratory coat. Avoid aerosol generation and direct contact with the powder or solution. Dispose of peptide-containing materials through approved institutional chemical and laboratory-waste procedures.
Technical Specifications and Molecular Attributes
| Attribute | Specification |
|---|---|
| Product | hGH Fragment 176–191, 5 mg, supplied with 3 mL bacteriostatic water |
| Common designation | hGH Fragment 176–191; hGH(176–191) |
| Sequence requiring confirmation | Commonly reported as H-YLRIVQCRSVEGSCGF-OH |
| Structural feature | Intramolecular disulphide bridge between cysteine residues |
| Residue count | 16 amino acids |
| IUPAC name | Full systematic peptide name should be confirmed on the CoA; sequence notation is preferred |
| CAS Registry Number | 66004-57-7 is widely reported; verify the exact form |
| Molecular formula | Form-dependent; reported records include C₇₈H₁₂₇N₂₃O₂₄S₂ and C₇₈H₁₂₅N₂₃O₂₃S₂ |
| Average molecular mass | Approximately 1,817–1,859 g/mol depending on terminal and salt form |
| Physical state and colour | Lyophilised white to off-white powder |
| Solubility profile | Aqueous compatibility may be feasible; pH, redox conditions and buffer composition require validation |
| Typical purity | Proposed target ≥99.0% by RP-HPLC; verify the actual lot-specific result |
| Identity testing | LC-MS, RP-HPLC and disulphide-state assessment |
| Companion reagent | 3 mL bacteriostatic water |
| Long-term storage | Typically −20°C or below, sealed and protected from light and moisture |
Because public records disagree on formula and mass, the product page should not state a single definitive molecular specification until the supplier provides a sequence-specific CoA. The material must also be distinguished from AOD-9604, which contains an additional N-terminal tyrosine.pubchem.ncbi.nlm.nih+3
Pharma Research .eu: Your Premier EU Vendor for High-Purity Reagents
Pharma Research .eu can position hGH Fragment 176–191 as a documented European disulphide-peptide reagent for analytical chemists, biochemists and laboratory managers. The product file should include a batch-specific CoA, SDS, exact sequence, terminal groups, disulphide-state information, purity result, identity data, salt-form information and storage instructions for both the peptide and bacteriostatic water.
Any claim that Pharma Research .eu operates an ISO 9001-certified quality-management system should be supported by a current certificate identifying the issuing body, scope and validity. Claims concerning discreet or temperature-controlled logistics across EU member states should likewise be verified for the destination, carrier route, packaging and applicable transport requirements.
A quality-focused supplier should be able to discuss:
-
The exact sequence and N-terminal residue.
-
Oxidised versus reduced peptide.
-
Free-peptide versus acetate or other salt form.
-
Distinction from AOD-9604.
-
RP-HPLC purity and LC-MS identity testing.
-
Residual solvents, moisture and elemental-impurity reporting.
-
Redox, buffer and container compatibility.
-
Storage, transport and documentation requirements.
Pharma Research .eu should therefore be described as a potential European source for research-grade hGH Fragment 176–191, with vendor-specific certification and logistics claims verified through current records. The material is intended strictly for controlled laboratory research and analytical use by qualified personnel under applicable institutional procedures.
MAECENAS IACULIS
Vestibulum curae torquent diam diam commodo parturient penatibus nunc dui adipiscing convallis bulum parturient suspendisse parturient a.Parturient in parturient scelerisque nibh lectus quam a natoque adipiscing a vestibulum hendrerit et pharetra fames nunc natoque dui.
ADIPISCING CONVALLIS BULUM
- Vestibulum penatibus nunc dui adipiscing convallis bulum parturient suspendisse.
- Abitur parturient praesent lectus quam a natoque adipiscing a vestibulum hendre.
- Diam parturient dictumst parturient scelerisque nibh lectus.
Scelerisque adipiscing bibendum sem vestibulum et in a a a purus lectus faucibus lobortis tincidunt purus lectus nisl class eros.Condimentum a et ullamcorper dictumst mus et tristique elementum nam inceptos hac parturient scelerisque vestibulum amet elit ut volutpat.


Reviews
There are no reviews yet.